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Abstract 
Background: Adjuvant therapies improve survival in gastric cancer; however, the role of 
adjuvant chemoradiation in the treatment of lymph node (LN)-positive gastric cancer 
remains uncertain.  This study sought to determine the role of adjuvant chemoradiation in 
addition to chemotherapy after resection for lymph node positive gastric cancer.  
Methods: The Surveillance, Epidemiology and End Results-Medicare linked data from 
2004-2013 was used to identify patients aged 66 and older with LN-positive gastric 
adenocarcinoma. Multivariable logistic regression evaluated factors associated with 
receipt of chemoradiation. The Kaplan-Meier method and Cox proportional hazards 
modeling were used to evaluate overall survival (OS). 
Results: A total of 2,409 patients with LN-positive gastric adenocarcinoma who 
underwent upfront surgical resection were identified; 309 (13%) received adjuvant 
chemotherapy and 407 (17%) received adjuvant chemotherapy and chemoradiation. 
Among all patients, median OS was 15 months. Median OS was 20 months for patients 
who received chemotherapy alone and 27 months for patients who received 
chemotherapy and chemoradiation (p<0.05). Recent diagnosis, older age, tumor stage T3 
or T4, and Charleston Comorbidity Index were associated with an increased hazard ratio 
for death (p<0.05). Receipt of chemoradiation was associated with a decreased hazard 
ratio for death (p<0.05).      
Conclusions: In patients with LN-positive gastric adenocarcinoma, the addition of 
chemoradiation to adjuvant chemotherapy after upfront surgical resection was associated 
with improved survival irrespective of the extent of lymphadenectomy. These data 
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suggest chemoradiation should be considered in patients with LN-positive gastric 
adenocarcinoma.  
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Introduction 
  
Gastric cancer is the sixth most frequently diagnosed cancer and the third most 
common cause of cancer related death worldwide(1). In the United states alone, it has an 
estimated incidence of 28,000 cases per year with an estimated 5-year survival of only 
30%(2). Most patients are diagnosed when the disease is confined to the stomach and 
surrounding lymph nodes(3), making surgical resection a hallmark of curative intent 
treatment. Amongst those with localized disease, 5-year survival approaches 70%; 
however this significantly decreases to 30% with regional disease spread and 5% with 
distant metastatic disease(3).  
Surgical resection is the mainstay of curative intent therapy and includes resection 
of the involved stomach, lymphadenectomy and anatomic reconstruction of the 
gastrointestinal tract. As over 50% of patients present with nodal involvement, 
locoregional recurrence is common (4). Due to the high rates of local, regional and 
distant recurrence in addition to the poor overall survival seen in gastric cancer, 
perioperative and adjuvant multi-modality treatments have been explored in an attempt to 
improve outcomes.  
Multiple randomized controlled trials have evaluated the role of adjuvant and 
perioperative therapy in addition to surgical resection(5-10). Chemotherapy and 
chemoradiation have both been shown to benefit patients with gastric cancer(7, 11, 12). 
The randomized controlled trial, Intergroup 0116 trial(11, 12), and a subsequent meta-
analysis(13) have shown that chemoradiation improves overall survival in resected 
gastric cancer. Two other randomized controlled trials established a survival and disease-
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free survival benefit to adjuvant chemotherapy compared to surgery alone(9, 10, 14). 
Notably, these trials were based in Japan and Korea, where an extensive D2 lymph node 
dissection is the standard of care(9, 10, 14). Despite many clinical trials, the optimum 
adjuvant treatment for resected cancer patients is still debated as a large proportion of 
patients in the Intergroup trial did not receive an extended (D2) lymph node dissection, 
and adjuvant treatment strategies had classically been compared to surgery alone, not one 
another. Many consider a D2 lymph node dissection standard of care surgery, and thus 
postulated that radiation portended a benefit in the setting of inadequate surgery.  
The Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) trial evaluated 
patients who received a gastrectomy with a D2 lymphadenectomy and compared the role 
of adjuvant chemotherapy alone to adjuvant chemotherapy with chemoradiation(5). The 
trial found no difference in survival between treatment groups; however, on subgroup 
analysis, the ARTIST trial identified a possible survival advantage in patients with lymph 
node-positive disease who received chemoradiation in addition to adjuvant 
chemotherapy(5). In order to further evaluate the role of adjuvant chemoradiation in 
addition to chemotherapy in patients with lymph node positive disease, the current study 
used a large national database to further investigate the role of adjuvant chemoradiation 
following upfront surgical resection of gastric adenocarcinoma in the United States. 
  
 
 
3 
Methods 
 After approval from the University of Minnesota Institutional Review Board, the 
National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER)-
Medicare linked data was used to identify patients aged 66 years and older who were 
diagnosed with gastric adenocarcinoma from 2004-2013. The SEER program registry is 
an aggregate of 18 distinct geographic cancer registries and represents approximately 
28% of the United States population (15). The SEER registry collects patient and tumor 
characteristics, including age at diagnosis, race, patient sex, primary tumor site, histologic 
subtype, tumor stage, tumor size, lymph node status, tumor grade, lymph node 
evaluation, diagnostic confirmation, type of surgery, vital status, and cause of death. 
SEER-Medicare linked data provides additional information on patient characteristics, 
demographics, tumor characteristics, treatment including surgical procedures, 
chemotherapy, and radiation as well as vital status through the Patient Entitlement and 
Diagnosis Summary File. Medicare claims data for hospitalizations and inpatient 
procedures are included in the Medicare Provider Analysis and Review and National 
Claims History files. Claims data for the year prior to diagnosis were used to calculate a 
Charlson Comorbidity Index (CCI). Cancer was excluded from the CCI, as it is the 
disease of interest in this study.   
Patients were included in this study if they had histologically confirmed lymph 
node-positive gastric adenocarcinoma, underwent upfront surgical resection and received 
adjuvant chemotherapy and/or chemoradiation. Patients were excluded if they received 
any form of neoadjuvant chemotherapy or radiation, had metastatic disease at diagnosis, 
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had non-adenocarcinoma gastric cancer, had gastroesophageal junction carcinomas, did 
not undergo surgical resection, had multiple primary malignancies, or were diagnosed by 
autopsy or death certificate.  
Patients who received adjuvant treatment were then divided into two cohorts, 
those who received adjuvant chemotherapy alone and those who received adjuvant 
chemotherapy and chemoradiation. Survival analysis for patients in both cohorts 
excluded patients who died within the first 3 months after diagnosis, based on the 
assumption that these patients had undiagnosed distant metastases or were too ill to 
receive a full course of treatment for their disease.   
Comparative statistics were used to analyze differences between demographic, 
tumor and treatment characteristics across patients in the two cohorts. Multivariable 
logistic regression analysis was performed to determine factors associated with receipt of 
chemoradiation. Survival was analyzed using the Kaplan-Meier method and Cox 
proportional hazard models. All Cox proportional hazard models included year of 
diagnosis, patient age, gender, race, tumor T-stage, number of lymph nodes examined, 
CCI, and type of adjuvant treatment. Results were considered statistically significant at a 
two-tailed p-value ≤0.05. All statistical analyses were performed with SAS software, 
version 9.3 (SAS Institute, Cary, NC). Sensitivity analyses were performed using the 
SEER database to ensure observed effects were not a product of older patient selection 
(SEER-Medicare). This analysis was performed using R software (R Foundation for 
Statistical Computing, Vienna, Austria, 2017).  
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Results 
A total of 2,409 patients were identified in the SEER-Medicare linked data set 
with lymph node positive gastric adenocarcinoma who underwent upfront surgical 
resection (Table 1). The median age of the cohort was 73 (interquartile range [IQR] 69-
77) and most patients were non-Hispanic white (56%). The majority of patients had T1 
and T2 tumors (61%). The median number of lymph nodes examined was 15 (IQR 9-23) 
and the median number of positive lymph nodes was 4 (IQR 2-9). Among all patients, 
1,693 (70%) did not receive any adjuvant therapy, 309 (13%) received chemotherapy 
alone, and 407 (17%) received adjuvant chemotherapy and chemoradiation. Patient and 
treatment characteristics for those who received adjuvant treatment are included in Table 
2. Patients who received chemotherapy and chemoradiation were younger than those who 
received chemotherapy alone (p=0.02). The median number of positive lymph nodes was 
5 (IQR 2-10) for those treated with chemotherapy and 4 (IQR 2-8) for those who received 
chemotherapy plus chemoradiation.  
 Multivariate regression was performed to evaluate patient factors associated with 
the receipt of chemoradiation among all patients with lymph node positive disease (Table 
3). Patients were less likely to receive chemoradiation if they were diagnosed in the more 
recent time period (2009-2013 compared to 2004-2008, p<0.05) or were older (75-79 
compared to 66-69; 80-84 compared to 66-69; ≥ 85 compared to 66-69, p<0.05). Patient 
gender, race, geographic location, T stage, CCI, and number of lymph nodes examined 
were not significantly associated with receipt of chemoradiation.   
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The median OS for all patients with lymph node positive gastric adenocarcinoma 
was 15 months. The median OS for patients treated only with adjuvant chemotherapy 
after surgery was 20 months, and the median OS for patients treated with adjuvant 
chemotherapy and chemoradiation was 27 months (Figure 1, p<0.05). The addition of 
chemoradiation to adjuvant chemotherapy was associated with improved survival, 
irrespective of the extent of lymphadenectomy performed (Figure 2). In patients who had 
less than 15 lymph nodes examined, median OS with chemotherapy alone was 16 months 
versus 25 months for those treated with chemotherapy and chemoradiation (Figure 2a, 
p<0.05). Among patients who had greater than 15 lymph nodes examined and were 
treated with chemotherapy, the median OS was 16 months versus 31 months for those 
treated with chemotherapy and chemoradiation (Figure 2b, p<0.05). 
A Cox-proportional hazards regression model was performed to further evaluate 
survival while adjusting for other patient factors (Table 4). More recent year of diagnosis 
(2009-2013 compared to 2004-2008), older age (75-79 compared to 66-69; ≥85 compared 
to 66-69), increased comorbidities (CCI of 1 compared to 0), and not receiving any 
adjuvant therapy (compared to chemotherapy alone) were all associated with a significant 
increase in the hazard ratio for death (p≤0.05). Non-white race and receipt of 
chemoradiation (compared to chemotherapy alone) were associated with a decreased 
hazard ratio for death (p≤0.05). The number of lymph nodes evaluated approached 
significance; in patients with greater than 15 lymph nodes evaluated the hazard ratio for 
death was 0.91 (95% confidence interval 0.83-1.0, p=0.05). 
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For all models, we performed several sensitivity analyses to ensure that the 
observed effects were not a product of the older patient selection inherent to utilizing the 
SEER-Medicare database. We utilized the SEER database to replicate our findings 
among patients of all ages diagnosed with lymph node positive gastric adenocarcinoma. 
For these analyses 5,063 patients were identified in the SEER database who underwent 
upfront surgical resection for lymph node positive stage I-III gastric adenocarcinoma. Of 
these, only 2,829 received adjuvant chemotherapy and were included in the subsequent 
sensitivity analyses. Under all assumptions, the conclusions remained unchanged 
(Appendix A).  
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Discussion 
The current study used a large national database to evaluate the role of adjuvant 
chemoradiation in patients with lymph node-positive gastric cancer who underwent 
surgical resection. Notably, 70% of patients did not receive any adjuvant therapy after 
surgical resection. Patients were less likely to receive chemoradiation if they were older 
or diagnosed in the more recent time period (2009-2013 compared to 2004-2008). The 
median OS for the entire cohort of patients diagnosed with lymph node-positive gastric 
cancer who underwent upfront resection was 15 months. The receipt of adjuvant 
chemotherapy alone was associated with an improvement in median OS to 20 months, 
and 27 months for those who received adjuvant chemotherapy and chemoradiation. On 
multivariable regression analysis, the addition of chemoradiation to adjuvant 
chemotherapy was associated with a reduction in the hazards ratio for death.  
Previous RCTs have demonstrated improved survival with the receipt of adjuvant 
or perioperative chemotherapy or chemoradiation following surgical resection of gastric 
adenocarcinoma (5-8, 10-12, 14). In the INT-0116 trial, patients were randomized 
adjuvant chemoradiation or observation alone after surgical resection(11). Those who 
received adjuvant chemoradiation had improved OS and locoregional recurrence 
compared to patients who treated with surgery alone, which persisted after more than 10 
years of follow-up (11, 12). The MAGIC trial established the benefit of perioperative 
epirubicin, cisplatin and fluorouracil over resection alone in gastric adenocarcinoma but 
did not evaluate the role of chemoradiation(7). While these trials have helped to define 
treatment algorithms for patients with resectable gastric adenocarcinoma, the role of 
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adjuvant chemoradiation in the setting of modern adjuvant chemotherapy remained 
uncertain. 
Two subsequent trials have attempted to examine the role of adjuvant 
chemoradiation in addition to chemotherapy. The ARTIST and CRITICS trials examined 
whether patients benefited from chemoradiation in addition to chemotherapy after 
surgical resection (5, 6, 8). The ARTIST trial found no improvement in disease-free 
survival (DFS) with the addition of chemoradiation (5, 6). However, post-hoc subgroup 
analysis of patients with nodal metastases found that there was improved 3-year DFS for 
those treated with chemotherapy plus chemoradiation versus chemotherapy alone after 
resection (77.5% and 72.3%, respectively, p=0.036)(6). The CRITICS trial similarly 
found no OS benefit to adjuvant chemoradiation following preoperative chemotherapy 
compared to perioperative chemotherapy alone (8). Unfortunately, the CRITICS trial did 
not include additional analyses of a lymph node-positive subgroup. The current study 
used a large national dataset to evaluate this clinical dilemma and found that the addition 
of chemoradiation to adjuvant chemotherapy was associated with improved survival in 
patients with lymph node-positive gastric adenocarcinoma.   
It is necessary to recognize that an important controversy in the management of 
gastric adenocarcinoma is the extent of lymphadenectomy performed during resection. 
The two major types of lymphadenectomy in gastric cancer are a less extensive D1 
lymphadenectomy and a more D2 lymphadenectomy (28). A D2 dissection has become 
the most widely recommended surgery internationally for resectable gastric cancer and 
has been shown to lead to a reduction in gastric-cancer specific deaths(16, 28, 29).  In 
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Asia, where the incidence of gastric adenocarcinoma is greater, most surgeons perform a 
more extensive, D2 lymphadenectomy due to improved oncologic outcomes, while many 
surgeons in North America and Europe perform a less extensive D1 dissection. In the 
Western population, the Dutch Gastric Cancer Trial compared D1versus D2 
lymphadenectomies and found that the D2 dissection was associated with significantly 
higher postoperative morbidity and mortality and no difference in OS at 5-years (4, 16-
18). However, longer term follow-up at 15 years demonstrated that D2 lymphadenectomy 
was associated with a significantly decreased risk of death from gastric adenocarcinoma 
(4). The United Kingdom Medical Research Council similarly performed a randomized 
trial of D1 versus D2 lymphadenectomies across Europe and found significantly higher 
in-hospital mortality in the D2 group but no difference between groups in OS at 5 
years(19). A more recent Italian study found comparable rates of morbidity, mortality and 
reoperation between patients receive a D1 and D2 lymphadenectomy, with rates 
comparable to those seen in the Japanese series (20). These improvements in surgical 
outcomes may be due to an increase in pancreas and spleen preserving 
lymphadenectomies in additional to technical improvements by surgeons. Importantly, 
however, it should be noted that in these trials, chemotherapy and chemoradiation were 
not included in the treatment protocols. With time, the D2 lymphadenectomy appears to 
be less morbid of an operation. 
Extent of lymphadenectomy was a criticism of the INT-0116 study, in which only 
10% of patients received the planned D2 dissection, 36% of patients received a D1 
dissection, and 54% received a D0 dissection (12). In that study, chemoradiation may 
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have compensated for suboptimal surgical therapy, which could explain the observed 
survival benefit attributed to chemoradiation. In the ARTIST and subsequent ARTIST-II 
trials, a D2 dissection was an inclusion criterion for the study, as the studies were based 
in Korean centers where it is standard of care. The results of the present study are based 
on the SEER-Medicare population in the United States, where a D2 lymphadenectomy is 
not standard. As the median number of lymph nodes examined was 15, it was unlikely 
that a high proportion of patients received a D2 lymphadenectomy. Nonetheless, when 
the survival analysis was stratified by number of lymph nodes examined (<15 versus ≥ 
15), the association between improved survival and chemoradiation persisted in both 
groups, suggesting a benefit to radiation irrespective of extent of dissection. Furthermore, 
the likelihood of receiving chemoradiation was not associated with the number of lymph 
nodes examined, suggesting that chemoradiation was not used to compensate for extent 
of lymphadenectomy.  
Importantly, this analysis of the SEER-Medicare database found that 70% of 
patients who underwent upfront surgical resection for LN-positive gastric 
adenocarcinoma received no adjuvant treatment, despite several RCTs demonstrating the 
advantage of multi-modality treatment in addition to surgical resection (5-11). This 
finding corroborates a previous review of the SEER-Medicare linked data from 2002-
2009, which found that only 38.6% of patients with stage III gastric adenocarcinoma 
received evidence-based care with appropriate adjuvant therapy (21). A similar review of 
the National Cancer Database found that 30.9% of patients did not receive any adjuvant 
chemotherapy or radiation, and that the use of radiation decreased throughout the study 
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period (2006-2013)(22). The present study demonstrated a similar trend of decreased 
utilization of chemoradiation in the United States over the course of this study (2004-
2013). 
It is important to address some of the limitations of this retrospective study. Use 
of an epidemiological and administrative dataset such as SEER introduces potential bias 
from missing data, coding inaccuracies and reporting bias. Additionally, as a 
retrospective study, we can only draw associations and not determine causality. 
Furthermore, SEER-Medicare data does not contain specific information on the exact 
chemotherapy and radiation regimens, resection margin status or the specific locations of 
the lymph node basins dissected. Thus, while lymphadenectomy is an important 
component of surgical resection for gastric adenocarcinoma, we can only infer extent of 
lymphadenectomy from the number of lymph nodes examined. Using the SEER-
Medicare dataset, only patients aged 65 years and greater can be evaluated. However, the 
median age of patients diagnosed with gastric cancer in the United States is 68 years, 
with more than 60% of patients diagnosed at age 65 or older, so the study population still 
represents the majority of patients with the gastric cancer (2, 23). Additionally, the 
findings presented here were replicated in SEER amongst patients of all ages as a part of 
the sensitivity analyses. Lastly recent RCTs such as the MAGIC trial have shown the 
benefit to perioperative chemotherapy(7), however in the present study all patients who 
received neoadjuvant therapy were excluded. While this potentially limits the 
applicability of the study in an era of perioperative treatment, it is important to note that 
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only 12-36% of patients actually receive neoadjuvant therapy (24, 25), making this study 
still applicable for the majority of patients with gastric adenocarcinoma.  
In conclusion, in the United States Medicare population, the addition of adjuvant 
chemoradiation to chemotherapy following upfront surgical resection for lymph node-
positive gastric cancer was associated with improved survival. The improved survival 
associated with chemoradiation persisted irrespective of the extent of lymphadenectomy 
performed; however, there was a greater associated improvement in median OS amongst 
those with a more extensive lymphadenectomy. Even after controlling for other relevant 
patient and treatment factors, the combination of adjuvant chemotherapy and 
chemoradiation was associated with improved survival. These data suggest that 
chemoradiation should be considered as a component of adjuvant therapy for patients 
with lymph node-positive gastric cancer following upfront surgical resection. Further 
studies, including randomized controlled trials, are needed to more closely define the role 
of adjuvant chemoradiation in node-positive gastric cancer, particularly with modern 
multi-modality therapy regimens.   
 
  
 
 
14 
Table 1: Patient characteristics of all patients with lymph node-positive gastric 
adenocarcinoma age 66 and above in the SEER-Medicare data set from 2004-2013 
(n=2,409) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Patients (%) 
Year of Diagnosis    
2004-2008 1343 (56) 
2009-2013 1066 (44) 
Age, year   
66-69 507 (21) 
70-74 583 (24) 
75-79 540 (23) 
80-84 487 (20) 
≥85 292 (12) 
Gender   
Male 1382 (57) 
Female 1027 (43) 
Race   
Non-Hispanic White  1344 (56) 
Black 302 (12) 
Other or Unknown 763 (32) 
Treating Institution   
Urban  2263 (94) 
Rural 146 (6) 
Tumor Stage   
T1 and T2 1469 (61) 
T3 766 (32) 
T4 174 (7) 
Charlson Comorbidity Index   
0 1259 (52) 
1 624 (26) 
2+ 526 (22) 
Number of Lymph Nodes Examined    
<15 1113 (46) 
15+ 1296 (54) 
Adjuvant Therapy   
None  1693 (70) 
Chemotherapy 309 (13) 
Chemotherapy + Chemoradiation 407 (17) 
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Table 2: Patient characteristics of patients with lymph node-positive gastric 
adenocarcinoma who were treated with adjuvant therapy in SEER-Medicare (2004-2013).  
 
  
Chemotherapy and 
Chemoradiation 
(n=407) 
Chemotherapy  
(n=309) p-value 
  Patients (%) Patients (%)   
Year of Diagnosis    0.003  
2004-2008 268 (66) 170 (55)   
2009-2013 139 (34) 139 (45)   
Age, years    0.02  
66-69 138 (34) 80 (26)   
70-74 131 (32) 90 (29)   
75-79 85 (21) 83 (27)   
≥80-84 53 (13) 56 (18)   
Gender    0.99  
Male 254 (62) 193 (62)   
Female 153 (38) 116 (38)   
Race    0.63  
Non-Hispanic White  235 (58) 183 (59)   
Black 44 (11) 38 (12)   
Other or Unknown 128 (31) 88 (29)   
Treating Institution    0.41  
Urban  380 (93) 293 (95)   
Rural 27 (27) 16 (5)   
Tumor Stage    0.24  
T1/T2 246 (60) 202 (65)   
T3 137 (34) 86 (28)   
T4 24 (6) 21 (7)   
Charlson Comorbidity 
Index    0.72 
 
0 221 (54) 161 (52)   
1 110 (27) 83 (27)   
2+ 76 (19) 65 (21)   
Number of Lymph Nodes 
Examined     0.70 
 
<15 181 (44) 133 (43)   
15+ 226 (56) 176 (57)   
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Table 3: Multivariable logistic regression of factors associated with the receipt of 
chemoradiation in patients with lymph node-positive gastric cancer in the SEER-
Medicare data from 2004-2013.   
  Odds Ratio 95% CI 
Year of Diagnosis  
2004-2008 1.00 Referent 
2009-2013 0.56 0.44 0.70 
Age, year  
66-69 1.00 Referent 
70-74 0.79 0.60 1.04 
75-79 0.47 0.35 0.64 
80-84 0.24 0.17 0.35 
≥85 0.11 0.06 0.21 
Gender  
Male 1.00 Referent 
Female 0.90 0.71 1.13 
Race      
Non-Hispanic White  1.00 Referent 
Black 0.73 0.51 1.04 
Other or Unknown 0.91 0.71 1.17 
Treating Institution      
Urban  1.00 Referent 
Rural 0.99 0.64 1.57 
Tumor Stage      
T1 and T2 1.00 Referent 
T3 1.10 0.87 1.40 
T4 0.77 0.48 1.22 
Charlson Comorbidity Index      
0 1.00 Referent 
1 1.04 0.80 1.36 
2+ 0.94 0.70 1.27 
Number of Lymph Nodes Examined      
<15 1.00 Referent 
15+ 1.05 0.84 1.32 
 
Bold text indicated statistical significance.   
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Table 4: Cox proportional hazards ratio for death among patients with lymph node-
positive gastric adenocarcinoma in SEER-Medicare from 2004-2013.  
 
  Hazard Ratio 95% CI p-Value 
Year of Diagnosis    
2004-2008 1.00 Referent 
2009-2013 1.56 1.41 1.71 <.0001 
Age, year   
66-69 1.00 Referent 
70-74 1.04 0.90 1.20 0.58 
75-79 1.22 1.05 1.41 0.01 
80-84 1.13 0.97 1.31 0.12 
≥85 1.32 1.11 1.56 0.0001 
Gender   
Male 1.00 Referent 
Female 1.07 0.97 1.17 0.19 
Race         
Non-Hispanic White  1.00 Referent 
Black 0.97 0.85 1.12 0.71 
Other or Unknown 0.80 0.72 0.89 <.0001 
Treating Institution         
Urban  1.00 Referent 
Rural 1.03 0.85 1.25 0.74 
Tumor Stage         
T1 and T2 1.00 Referent 
T3 0.71 0.64 0.78 <.0001 
T4 1.14 0.96 1.36 0.14 
Number of Lymph Nodes Examined          
<15 1.00 Referent 
15+ 0.91 0.83 1.00 0.05 
Charlson Comorbidity Index         
0 1.00 Referent 
1 1.14 1.02 1.27 0.02 
2+ 1.12 0.99 1.26 0.07 
Adjuvant Therapy         
None 1.41 1.22 1.62 <.0001 
Chemotherapy Alone  1.00 Referent 
Chemoradiation 0.77 0.64 0.92 0.004 
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Bold text indicated statistical significance. 
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Figure 1: Kaplan Meier survival curve of patients with lymph node-positive gastric 
adenocarcinoma, stratified by type of adjuvant treatment. Median survival 20 months for 
patients treated with chemotherapy and 27 months for patients with chemotherapy and 
chemoradiation, p<0.05.  
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Figure 2: Kaplan Meier survival curve stratified by extent of lymphadenectomy. A) 
Kaplan Meier survival curve of patients with less than 15 lymph nodes examined treated 
with chemotherapy or chemotherapy and chemoradiation. Median survival for patients 
treated with chemotherapy is 16 months and median survival for patients treated with 
chemoradiation is 25 months (p<0.05). B) Kaplan Meier survival curve of patients with 
15 or more lymph nodes examined treated with chemotherapy or chemotherapy and 
chemoradiation. Median survival for patients treated with chemotherapy was 16 months 
and 31 months for those treated with chemotherapy and chemoradiation (p<0.05).   
A) 
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Appendix  
 
Sensitivity analysis performed in SEER including patients diagnosed with lymph node 
positive gastric cancer from 2004-2013 who underwent upfront surgical resection and 
adjuvant chemotherapy.  
 
Table A1: Patient characteristics of SEER cohort 
 
Patient Characteristic  Chemotherapy Chemotherapy and Radiation p 
  n=884 n=1945  
Year of Diagnosis (%) 2004-2008 371 (42.0) 1016 (52.2) <0.001 
 2009-2013 513 (58.0) 929 (47.8)  
Patient Age (%) 10-20 0 (0.0) 2 (0.1) 0.196 
 20-29 3 (0.3) 17 (0.9)  
 30-39 49 (5.5) 88 (4.5)  
 40-49 114 (12.9) 261 (13.4)  
 50-59 200 (22.6) 495 (25.4)  
 60-69 239 (27.0) 535 (27.5)  
 70-79 215 (24.3) 434 (22.3)  
 80+ 64 (7.2) 113 (5.8)  
Sex (%) Female 390 (44.1) 850 (43.7) 0.868 
 Male 494 (55.9) 1095 (56.3)  
Race (%) Black 136 (15.4) 354 (18.2) 0.021 
 Other  203 (23.0) 513 (26.4)  
 Unknown 3 (0.3) 7 (0.4)  
 White 542 (61.3) 1071 (55.1)  
T Stage (%) T1 76 (8.6) 158 (8.1) <0.001 
 T2 480 (54.3) 1121 (57.6)  
 T3 296 (33.5) 647 (33.3)  
 T4 8 (0.9) 7 (0.4)  
 TX 24 (2.7) 12 (0.6)  
Number of Lymph 
Nodes Evaluated (%) </=15 434 (49.1) 977 (50.2) 0.603 
 >15 450 (50.9) 968 (49.8)  
Number of Positive 
Nodes (mean (sd))  5.53 (4.56) 5.51 (4.22) 0.929 
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Figure A1: Kaplan-Meier survival curve including all patients with lymph node positive 
gastric cancer in SEER treated with adjuvant chemotherapy alone or adjuvant 
chemotherapy and radiation. Median survival 24 months for those treated without 
radiation and 35 months for those treated with radiation (p<0.0001) 
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Figure A2: Kaplan-Meier survival curve including all patients with lymph node positive 
gastric cancer stratified by extent of lymphadenectomy. A) Patients with a lymph node 
dissection of >15 nodes. Median overall survival was 28 months with chemotherapy 
alone and 41 months with chemotherapy and chemoradiation (p<0.0001). B) Patients 
with a lymph node dissection ≤15, median overall survival was 21 months with 
chemotherapy alone and 30 months with chemotherapy and chemoradiation (p<0.0001). 
A) 
 
B) 
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Table A2: Cox proportional hazards ratio for death model performed in SEER.  
 
 Hazard Ratio 95% Confidence Interval p value 
Radiation None Referent   
 Yes 0.738 0.670 0.814 <0.001 
Gender Male Referent   
 Female 0.976 0.890 1.071 0.611 
T Stage T1 Referent   
 T2 1.789 1.452 2.203 <0.001 
 T3 3.016 2.439 3.731 <0.001 
 T4 3.091 1.727 5.533 <0.001 
 Tx 2.010 1.291 3.128 0.002 
Year of Diagnosis 2004-2008 Referent   
 2009-2013 0.936 0.851 1.030 0.174 
Race Black Referent   
 Other 0.802 0.694 0.926 0.003 
 Unknown 0.131 0.018 0.937 0.430 
 White 0.917 0.810 1.038 0.172 
Age 10-19 Referent   
 20-29 1.153 0.147 9.047 0.892 
 30-39 1.097 0.152 7.915 0.927 
 40-49 1.149 0.161 8.220 0.890 
 50-59 1.188 0.166 8.486 0.864 
 60-69 1.230 0.172 8.788 0.836 
 70-79 1.497 0.210 10.697 6.880 
 80+ 1.794 0.250 12.884 0.561 
Nodes Evaluated </=15 Referent   
 >15 0.703 0.640 0.772 <0.001 
      
 
